The Hematologic Malignancy Center at Dana-Farber/Boston Children's is one of the top centers of its kind in the world. We offer specialized programs for the treatment of leukemia, lymphoma, histiocytosis and lymphadenopathy. Our center played a key role in refining treatment for childhood leukemia, resulting in today's cure rates of more than 90 percent for pediatric acute lymphoblastic leukemia, and we continue to lead high-impact clinical trials designed to increase cure rates and decrease treatment-related toxicities for long-term survivors.
Highlights of the Hematologic Malignancy Center include:
A specialized program for patients receiving cancer treatment who have experienced a decrease or loss of reproductive function.
Providing care and advocacy for survivors of childhood cancer through ongoing education, support and research on the long-term effects of cancer treatments.
Social workers, psychologists and resource specialists offering help with the social, emotional, and psychological aspects of caring for children with cancer.
Phone: 617-632-5508Online form: Request an appointment
U.S. News & World Report ranked Dana-Farber/Boston Children's the #1 pediatric cancer hospital in the nation.
Sarah Levin is 11 years old, and has beaten acute lymphoblastic leukemia (ALL) twice. This is her story in her own words on the Boston Children's Hospital Blog Thriving.
Dana-Farber/Boston Children's is a teaching affiliate of Harvard Medical School.